ArticleOncology letters2026
Influence of the second primary cancer on clinical outcomes of nasopharyngeal carcinoma following definitive chemoradiotherapy.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer characterized by undifferentiated histopathological features and a notably high incidence in Taiwan and Southeastern China. Advances in NPC diagnosis and treatment have led to improved prognosis and long-term survival rates. Compared with other head and neck cancers, NPC tends to occur at a younger age, and is associated with a relatively higher rate of second primary cancers (SPCs) that may develop during follow-up. Therefore, investigating the risk of SPCs in a non-metastatic NPC cohort treated with concurrent chemoradiotherapy (CCRT) is essential for developing tailored follow-up strategies. Patients with pathologically confirmed NPC were retrospectively enrolled between January 2012 and December 2022. The primary outcome of this study was overall survival (OS). A total of 161 eligible patients were analyzed. During a median follow-up period of 4.5 years, seven patients developed SPCs, yielding a crude incidence rate of 4.3%. The lung was the most common SPC site (42%, n=3). The median interval from NPC diagnosis to the first SPC was 2.7 years. Kaplan-Meier analysis with the log-rank test indicated that SPC development significantly affected OS (P=0.049). Using Firth's logistic penalized Cox regression, univariate analysis showed that the absence of SPCs [hazard ratio (HR)=0.27, 95% confidence interval (CI): 0.09-0.86] was associated with favorable OS, whereas older age (≥65 years) (HR=3.66, 95% CI: 1.60-8.40) was associated with worse OS. In the multivariate analysis, only older age (≥65 years) (HR=3.34, 95% CI: 1.43-7.80) remained significantly associated with unfavorable OS. Post-CCRT follow-up for patients with NPC should include surveillance not only for recurrence but also for the potential development of SPCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.